Treatment of hepatitis C infection in haemophiliacs: the Edinburgh experience

Hanley, JP; Jarvis, L M; Andrews, Janet I.; Hayes, Peter; Simmonds, Peter; Ludlam, C. A.

doi:10.1111/j.1365-2516.1995.tb00130.x

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although we have commenced interferon-a in a small number of patients, we recognize its limitations. In a series from Edinburgh, only one of 32 haemophiliac patients had a sustained response to 6 months of interferon-a therapy (Hanley et al, 1995), whereas in a similar series of 27 patients at the Royal Free Hospital, only one had a sustained response (Telfer, 1995).…”

Section: Discussionmentioning

confidence: 91%

The role for liver biopsy in haemophiliacs infected with the hepatitis C virus

et al. 1997

View full text Add to dashboard Cite

Assessment of chronic hepatitis C virus infection requires a liver biopsy in most circumstances. There is a reluctance to perform liver biopsy in haemophiliacs because of a perceived risk of haemorrhage, although with adequate factor concentrate replacement in patients without factor concentrate inhibitors it should be safe. We report a 4‐year experience of liver biopsy in patients with haemophilia infected with chronic hepatitis C virus. Of 55 patients seropositive for anti‐HCV, 35 have undergone liver biopsy; the median age of this group was 33 years (range 13–68). Seven patients had a normal liver. 22 had portal tract inflammation, four with lymphoid aggregates. Mild piecemeal necrosis was observed in only two and no bile duct injury was found. 11 patients had mild mixed micro‐ and macro‐vesicular fat. 19 patients had no evidence of fibrosis despite an estimated median duration of disease of 20 years (range 8–43). In the remaining 16 patients the maximum degree of fibrosis achieved was stage III. Patients with more significant fibrosis could not be identified on the basis of ALT or HCV RNA. There were no complications of liver biopsy in this series. Liver biopsy following a well‐defined protocol in chronic hepatitis C virus haemophiliac carriers is safe in the absence of factor concentrate inhibitors. In this young group of patients without HIV infection there was no evidence of significant liver disease despite a considerable duration of disease. Performing liver biopsy allows accurate information to be given to the patient and avoids unnecessary therapy. The relative youth of this group may be important in the light of the benign histology.

show abstract

Section: Discussionmentioning

confidence: 91%

The role for liver biopsy in haemophiliacs infected with the hepatitis C virus

et al. 1997

View full text Add to dashboard Cite

show abstract

Interferon therapy for Japanese hemophiliacs with chronic hepatitis C

Miura

Meguro

Takayama

et al. 1997

Pediatrics International

View full text Add to dashboard Cite

Eight Japanese hemophiliacs with chronic hepatitis C (CHC) received interferon (IFN) therapy and four of them (50%) responded completely. Non-responders included 3 double-infected patients: I with hepatitis B virus (HBV) and 2 with human immunodeficiency virus-I t HIV-I 1. In one of the patients with H I V -1 double infection, the absolute number of C M ' lymphocytes decreased during IFN therapy. These findings suggest that hemophiliac patients with CHC can respond well to IFN therapy. but in patients who are double-infected with HBV and HIV-I. the indication of IFN therapy should he considered seriously. Key words chronic hepatitis, double infection, hemophilia. hepatitis C virus. interferon.Recently, interferon (IFN) has been used as the main

show abstract